Trials Annotator

Org. Study IDs: CC-5013-TCL-001
Secondary IDs: 2007-002171-13

Last trial update was posted on 2019-11-25

Lenalidomide

Lymphoma Lymphoma, Non-Hodgkin Lymphoma, T-Cell

T-cell Non-Hodgkin's Lymphoma

Decision not to pursue as single agent in the study population.

N/A

Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer. 2013 Sep;49(13):2869-76. doi: 10.1016/j.ejca.2013.04.029. Epub 2013 May 31. [PMID: 23731832] [DOI: 10.1016/j.ejca.2013.04.029]

No annotators decided on categories yet

#	Outdated	Intervention				Condition
#	Outdated	Name		Route	DrugBank ID	Condition